Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Up-front red blood cell transfusion followed by maintenance epoetin alfa during chemotherapy for anemic patients with solid tumors
NL-OMON26479Phase 2Active, not recruiting
- Sponsor
- Not applicable.
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epoetin alfa in anaemia and Nonhematologic neoplasms, sponsored by Not applicable. Primary endpoints: Hemoglobin levels before and during chemotherapy and Safety of the pCATS anemia treatment regimen. Started Sep 2005; status: active, not recruiting.
02
Drugs
epoetin alfa
03
Conditions
anaemiaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON26479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26479.